Stacie M. Jones

High Impact

Professor

University of Arkansas for Medical Sciences

faculty

68 h-index 441 pubs 20,960 cited

Research Areas

Food composition and properties Immune Response and Inflammation Child and Adolescent Health T-cell and B-cell Immunology Monoclonal and Polyclonal Antibodies Research Health and Medical Research Impacts Meta-analysis and systematic reviews Food Allergy and Anaphylaxis Research

Links

ORCID Lab Website Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Stacie M. Jones, Professor at the University of Arkansas for Medical Sciences, conducts research focused on food allergies and immunotherapy. Her work investigates the efficacy and safety of various treatment modalities, including omalizumab and oral immunotherapy, particularly in pediatric populations. Jones has published research on updating grading scales for allergic reactions and exploring the role of allergen-specific T cells in food allergy.

Her research group includes collaborators such as Amy M. Scurlock, Robbie Pesek, Brandi Whitaker, and Emily Seminara, all from the University of Arkansas for Medical Sciences. Jones maintains an active lab website detailing her group's ongoing projects. Her scholarship is recognized by a high-impact researcher designation, evidenced by her h-index of 68 and over 20,000 citations across 441 publications.

Metrics

h-index: 68
Publications: 441
Citations: 20,960

Selected Publications

Genetic Determinants of Peanut‐Specific <scp>IgG4</scp> Levels in the Context of Sustained Oral Peanut Exposure in the <scp>LEAP</scp> Study (2026) DOI
Introduction of allergenic foods after treatment with omalizumab (2025) DOI
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE (2025) DOI
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy (2024) DOI
Omalizumab Implementation in Practice: Lessons Learned From the OUtMATCH Study (2024) DOI
Impact of Atopic Status on Clinical Presentation and Treatment Response in Pediatric Patients With Eosinophilic Esophagitis (2024) DOI
Enhanced Gut Microbiome Capacity for Amino Acid Metabolism is associated with Peanut Oral Immunotherapy Failure (2024) DOI
Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy (2024) DOI
Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial (2024) DOI
Food insecurity and allergic diseases: A call to collective action (2023) DOI
Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age (2023) DOI
Longitudinal dynamics of the gut microbiome and metabolome in peanut allergy development (2023) DOI
The SunBEAm birth cohort: Protocol design (2023) DOI
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy (2023) DOI
Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy (2023) DOI